Analysts Set $32.25 Price Target for Menlo Therapeutics (MNLO)

Shares of Menlo Therapeutics (NASDAQ:MNLO) have received an average broker rating score of 1.50 (Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and three have assigned a strong buy recommendation to the company. Menlo Therapeutics’ rating score has declined by 50% from three months ago as a result of various analysts’ ratings changes.

Brokers have set a one year consensus target price of $32.25 for the company and are predicting that the company will post ($0.84) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Menlo Therapeutics an industry rank of 156 out of 265 based on the ratings given to related companies.

MNLO has been the topic of a number of analyst reports. Jefferies Group downgraded Menlo Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 9th. JMP Securities initiated coverage on Menlo Therapeutics in a research report on Tuesday, February 20th. They set an “outperform” rating and a $44.00 price objective on the stock. Guggenheim initiated coverage on Menlo Therapeutics in a research report on Monday, February 19th. They set a “buy” rating and a $52.00 price objective on the stock. Piper Jaffray Companies initiated coverage on Menlo Therapeutics in a research report on Tuesday, February 20th. They set an “overweight” rating and a $48.00 price objective on the stock. Finally, ValuEngine upgraded Menlo Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd.



Shares of Menlo Therapeutics stock opened at $9.00 on Wednesday. Menlo Therapeutics has a one year low of $6.99 and a one year high of $39.86.

Menlo Therapeutics (NASDAQ:MNLO) last announced its quarterly earnings data on Wednesday, May 9th. The company reported ($0.72) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.66) by ($0.06). The company had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.56 million. equities research analysts anticipate that Menlo Therapeutics will post -3.19 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of MNLO. BlackRock Inc. acquired a new stake in Menlo Therapeutics during the first quarter worth $17,185,000. VHCP Management II LLC acquired a new stake in Menlo Therapeutics during the first quarter worth $12,777,000. Rock Springs Capital Management LP acquired a new stake in Menlo Therapeutics during the first quarter worth $12,401,000. Franklin Resources Inc. acquired a new stake in Menlo Therapeutics during the first quarter worth $7,516,000. Finally, JPMorgan Chase & Co. acquired a new stake in Menlo Therapeutics during the first quarter worth $4,329,000. 65.67% of the stock is owned by institutional investors.

Menlo Therapeutics Company Profile

Menlo Therapeutics Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis.

Get a free copy of the Zacks research report on Menlo Therapeutics (MNLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply